Home  »  Companies   »  Analysts suggest Sage Therapeutics Inc. (SAGE) cou...

Analysts suggest Sage Therapeutics Inc. (SAGE) could spike 57.82% in a year

Sage Therapeutics Inc. (NASDAQ: SAGE) is -8.82% lower on its value in year-to-date trading and has touched a low of $33.82 and a high of $98.39 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The SAGE stock was last observed hovering at around $77.67 in the last trading session, with the day’s gains setting it 1.21% off its average median price target of $100.00 for the next 12 months. It is also 57.82% off the consensus price target high of $187.00 offered by 22 analysts, but current levels are -12.69% lower than the price target low of $70.00 for the same period.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Currently trading at $78.88, the stock is 3.72% and 2.13% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.45 million and changing 1.56% at the moment leaves the stock 12.16% off its SMA200. SAGE registered 94.67% gain for a year compared to 6-month gain of 11.41%. The firm has a 50-day simple moving average (SMA 50) of $75.89 and a 200-day simple moving average (SMA200) of $78.28.

The stock witnessed a 7.64% loss in the last 1 month and extending the period to 3 months gives it a -0.49%, and is 5.57% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.35% over the week and 4.47% over the month.

Sage Therapeutics Inc. (SAGE) has around 675 employees, a market worth around $4.50B and $1.11B in sales. Current P/E ratio is 7.70. Profit margin for the company is 54.40%. Distance from 52-week low is 133.23% and -19.83% from its 52-week high. The company has generated returns on investments over the last 12 months (28.80%).

Sage Therapeutics Inc. (SAGE) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Sage Therapeutics Inc. (SAGE) is a “Overweight”. 22 analysts offering their recommendations for the stock have an average rating of 1.90, where 8 rate it as a Hold and 0 think it is a “Overweight”. 14 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Sage Therapeutics Inc. is expected to release its quarterly report on 08/10/2021 and quarterly earnings per share for the current quarter are estimated at -$1.91 with sales reaching $2M over the same period.The EPS is expected to grow by 185.50% this year, but quarterly earnings will post -98.40% year-over-year. Quarterly sales are estimated to shrink -12.50% in year-over-year returns.

Sage Therapeutics Inc. (SAGE) Top Institutional Holders

368 institutions hold shares in Sage Therapeutics Inc. (SAGE), with 7.18M shares held by insiders accounting for 12.30% while institutional investors hold 106.54% of the company’s shares. The shares outstanding are 52.12M, and float is at 51.11M with Short Float at 8.63%. Institutions hold 93.44% of the Float.

The top institutional shareholder in the company is FMR, LLC with over 7.81 million shares valued at $675.36 million. The investor’s holdings represent 13.37% of the SAGE Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 4.6 million shares valued at $397.87 million to account for 7.88% of the shares outstanding. The other top investors are Wellington Management Group, LLP which holds 4.28 million shares representing 7.34% and valued at over $370.58 million, while Blackrock Inc. holds 4.98% of the shares totaling 2.91 million with a market value of $251.77 million.

Sage Therapeutics Inc. (SAGE) Insider Activity

A total of 3 insider transactions have happened at Sage Therapeutics Inc. (SAGE) in the last six months, with sales accounting for 0 and purchases happening 3 times.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Sage Therapeutics Inc. (SAGE): Who are the competitors?

The company’s main competitors (and peers) include Intercept Pharmaceuticals Inc. (ICPT) that is trading -75.58% down over the past 12 months. Short interest in the company’s stock has risen 13.53% from the last report on Apr 14, 2021 to stand at a total of 4.41 million short shares sold with a short interest ratio of 8.93.

Related Posts

VNUE Makes Good Progress

VNUE Inc (VNUE) closed the last session almost stable at $0.0112 after seeing a rise of just 1.82% that brought its market cap to $15.81M.




Download Free eBook For

100% free. stop anytime no spam